 "Aurobindo Pharma")
Shares of Aurobindo Pharma slipped 17 per cent at Rs 498 on the BSE on Monday after in a surprise development, the US drug regulator FDA revoked the ‘Voluntary Action Initiated’ status issued to company’s plant in Hyderabad, days after indicating it might not pursue further regulatory action.
Aurobindo Pharma has received further communication from the US Food and Drug Administration USFDA on its Unit IV injectable plant stating that the inspection is still open and under review. The letter issued on February 19, mentions that the establishment inspection report (EIR) with voluntary action indicated (VAI) classification for the
Aurobindo Pharma has received further communication from the US Food and Drug Administration USFDA on its Unit IV injectable plant stating that the inspection is still open and under review. The letter issued on February 19, mentions that the establishment inspection report (EIR) with voluntary action indicated (VAI) classification for the
